Business Wire

DNA-ELECTRONICS

Del
Ability of Semiconductor DNA Sequencing to Transform Healthcare and Save Lives Recognised by the 2014 Faraday Medal to Professor Chris Toumazou

DNA Electronics (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary point-of-need test for sepsis, announces today that its founder, Chairman and CEO Professor Chris Toumazou FRS, FREng, FMEDSci, FIET, FIEEE, FCGI, FRSM has been awarded the UK Institution of Engineering and Technology (IET)’s highest honour, the 2014 Faraday Medal. Named after Michael Faraday, the medal which dates back to 1922 recognises Professor Toumazou’s pioneering work in the invention of semiconductor DNA sequencing and its ability to revolutionise healthcare and save lives.

Professor Toumazou’s semiconductor based sequencing technology enables rapid, cheap and even disposable DNA sequencing. As a microchip-based system, unlike optical technologies, it can be scaled down enabling DNA sequencing to be performed on a device the size of a USB stick. In June this year Professor Toumazou’s technology was also recognised by the European Patent Office when he was awarded the prestigious 2014 European Inventor of the Year Award for Research.

The principle and commercial utility of Professor Toumazou’s invention has already been proven as one of the leading next generation sequencing (NGS) technologies. Under licence from DNAe, this portable and rapid semiconductor DNA sequencing technology is the basis of Thermo Fisher’s Ion Torrent™ bench-top DNA sequencing systems and has now become a multi-billion dollar industry.

Dr Steve Allen, COO of DNAe said: “At DNAe we are working to commercialise semiconductor DNA sequencing technology for the consumer healthcare market where rapid near-patient live diagnosis is needed to provide actionable information to clinicians. Our priority focus is the development of Genalysis® point-of-need tests for diagnosis of infectious diseases, particularly those leading to sepsis, where speed and DNA-specific information can make the difference between life and death, and accurate diagnostics can help to address the global crisis of antimicrobial resistance.”

Tackling sepsis by developing a point-of-need rapid diagnostic test addresses the challenge of the Longitude Prize. 37,000 people die in the UK every year from sepsis, more than diseases such as lung cancer, and time is a critical factor in survival. Professor Toumazou’s invention will enable clinicians to intervene before sepsis sets in to diagnose rapidly and accurately what infection a patient has and to help select the antibiotic that will work to treat the disease.

Commenting on the award, Chairman and CEO of DNAe, Professor Chris Toumazou said: “I am very thankful to the Institution for considering my work for this prestigious award. Being chosen as the 2014 winner is a true honour. For my entire career I have worked to bring electronic inventions to healthcare markets where there is a critical and urgent need. For me, the ability to use semiconductor sequencing to provide a medical diagnosis in just a few hours that once took days is a crucial step in saving the lives of patients. This is particularly significant for the treatment of sepsis where every minute matters.”

Tan Sri Lim Kok Thay, CEO and Chairman of Genting Berhard, a major shareholder in DNAe with a growing portfolio of cutting–edge healthcare companies said: “It is great to see Professor Toumazou’s outstanding achievement in turning microchip technology into game-changing semiconductor sequencing devices recognised by the IET. DNAe’s application of this technology to address the huge unmet medical need for rapid point-of-need testing for sepsis makes them a stand out company that we are proud to back.”

Previous winners of the award include Professor Sir Michael Pepper FREng, FRS, for pioneering contributions to advanced semiconductor structures in 2013, Dr Leonardo Chiarigliona for pioneering contributions to digital media in 2012, and Professor Donald E Knuth for pioneering contributions in computer sciences in 2011.

—Ends—

About DNA Electronics – www.dnae.co.uk

DNA Electronics Ltd (DNAe) is commercialising its semiconductor DNA sequencing technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling the right treatment at the right time. DNAe’s priority focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. The Company’s first test will be a DNA diagnostic for use in the management of sepsis.

DNAe’s Genalysis® system is a sample-to-result genomic analysis platform based on semiconductor sequencing, built into a USB-sized device for use at the patient point-of-need to diagnose accurately and very rapidly what infection a patient has and to help select the antibiotics that will work to treat the disease.

Through a non-exclusive license to Thermo Fisher, DNAe’s semiconductor sequencing technology is the core of the Ion Torrent™ Next Generation Sequencing (NGS) systems, proving its performance at the laboratory scale. DNAe’s semiconductor sequencing is more scalable than any other NGS technology available and is thus amenable to nano-scale consumer applications, delivering rapid, accurate and cheap sequence information from a device the size of a USB stick.

A venture capital backed Company employing over 70 staff at its headquarters in London UK, DNAe’s management team is highly experienced in the development and commercialisation of DNA sequencing technologies and is led by CEO and highly acclaimed inventor Professor Chris Toumazou.

About Professor Professor Chris Toumazou, FRS, FREng, FMEDSci, FIET, FIEEE, FCGI, FRSM, DEng, PhD, BSc

Chris is London’s first Regius Professor of Engineering, at Imperial College London where he holds a Chair in Biomedical Circuits in the Department of Electrical and Electronic Engineering. He is also Director of the Centre for Bio-Inspired Technology, Founder and Chief Scientist of the Institute of Biomedical Engineering, and Chairman and CEO of DNA Electronics. DNA Electronics is developing point-of-need diagnostics for life-threatening infectious diseases, based on Chris’ semiconductor DNA sequencing technology. In recognition of this invention he won the 2014 European Inventor Award from the EPO and was awarded the Royal Society Gabor Medal 2013.

Professor Toumazou’s research is dedicated to saving and improving lives through the invention of revolutionary, innovative and disruptive technologies, including the creation of a leading edge medical research institute as well as spin-out ventures to commercialize his ground-breaking inventions namely DNA Electronics Ltd and Toumaz Group plc.

About the Faraday Medal – www.theiet.org/achievement

The Faraday Medal of the IET is a bronze medal established to commemorate the fiftieth anniversary of the first Ordinary Meeting of the Society of Telegraph Engineers, a predecessor organisation of the Institute of Engineering and Technology (IET). The IET’s most prestigious award to an individual, this medal dates back to 1922. The medal is awarded for notable scientific or industrial achievement in engineering, or for conspicuous service rendered to the advancement of science, engineering and technology or for lifetime achievement in science, engineering or technology.

Contact:

DNA Electronics Ltd
Professor Chris Toumazou, Chief Executive Officer
Dr Steve Allen, Chief Operating Officer
Tel: +44 (0)20 7036 2100
or
Instinctif Partners (media relations)
Sue Charles / Jen Lewis / Alex Bannister
Tel: +44 (0)20 7457 2020
Email: DNAe@instinctif.com

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options4.6.2025 20:19:00 CEST | Press release

The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer drug in patients with breast and lung cancer and active brain metastases, and leptomeningeal disease from solid tumors. These results were presented as an oral presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, with select results simultaneously published in Nature Medicine. MEDSIR’s DEMETHER clinical trial was mentioned during abstract discussion due to the relevance of its strategy. Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II study funded by Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, evaluates the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases and leptomeningeal disease, serious compli

QPS Celebrates 30th Anniversary4.6.2025 18:00:00 CEST | Press release

QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS is now recognized as a global leader in contract research. Over the past 30 years, the company has grown from a single office in Delaware, USA to a widely respected, global, full-service CRO with 8 locations spread across the US, EU, Asia, India and Australia, a clinical trial network of over 700 sites and an increased focus on leveraging the power of AI to accelerate clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604778675/en/ Dr. Benjamin Chien founder and CEO of QPS Holdings, LLC. Over the years, QPS has grown from a small molecule bioanalysis shop of three people to a globa

Cessna SkyCourier Combi Configuration Achieves Certification From the National Civil Aviation Agency of Brazil4.6.2025 17:30:00 CEST | Press release

Cleiton Táxi Aéreotakes first delivery in South America for charter operations The Cessna SkyCourier Combi configuration kit recently achieved certification from the National Civil Aviation Agency of Brazil (ANAC) and joined the fleet of Brazilian charter company Cleiton Táxi Aéreo (CTA). This marks the first delivery of the SkyCourier into South America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604928791/en/ The Cessna SkyCourier Combi configuration kit recently achieved certification from the National Civil Aviation Agency of Brazil (ANAC) and joined the fleet of Brazilian charter company Cleiton Táxi Aéreo (CTA). This marks the first delivery of the SkyCourier into South America. (Photo credit: Textron Aviation) The Cessna SkyCourier is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. CTA recently took delivery of a passenger variant of the twin-engine, large-utility turbopr

IFF Unveils Game-Changing Outlook on GLP-1 Consumers4.6.2025 17:00:00 CEST | Press release

New research reveals how food and beverage brands can lead innovation for millions facing sensory and nutritional challenges IFF (NYSE: IFF), a global leader in food, beverage, and health and wellness, has released a new report highlighting how the rapidly growing GLP-1 consumer market is reshaping the sensory experience and nutritional needs associated with eating and drinking. The report outlines how food and beverage manufacturers can better support this emerging consumer segment with products that align with their evolving preferences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604818126/en/ “IFF is empowering our customers to lead the next wave of food and beverage innovations beyond traditional formulations, including helping GLP-1 consumers have choices they desire,” said Erik Fyrwald, IFF CEO. “We aim to bring back the joy of eating and drinking by offering more healthy, great-tasting nutrition choices for all

Visa Cash App Racing Bulls (VCARB) Formula One™ Team Accelerates Racing Car Design with Neural Concept’s Engineering AI4.6.2025 16:04:00 CEST | Press release

Visa Cash App Racing Bulls Formula One™Team has deployed Neural Concept, the world’s leading AI platform for engineering design to accelerate the team’s car design and optimize aerodynamic performance through AI-powered, data-driven engineering workflows that enable faster design iteration and better-informed decisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603592297/en/ Visa Cash App Red Bull - Racing Bulls and Neural Concept AI F1 vehicle partnership Neural Concept’s proprietary Engineering AI platform complements traditional Computational Fluid Dynamics (CFD) with high-speed predictive simulations. Engineers can use digital twins to evaluate thousands of design variants across complex “multi-physics” environments that mimic real-world track conditions such as wind and temperature differences. This enables VCARB to explore more designs, unlocking new performance gains within every iteration. Laurent Mekies, Tea

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye